Candel Therapeutics Reports Initial Survival Data From Phase 2 Clinical Trial Of CAN-2409 In Non-Small Cell Lung Cancer; Says 'Initial Data Suggests 12-Month Survival Is Consistent With An Increased Tail On The Maturing Survival Curve'
Portfolio Pulse from Bill Haddad
Candel Therapeutics has reported initial survival data from its Phase 2 clinical trial of CAN-2409 in non-small cell lung cancer. The initial data suggests that the 12-month survival is consistent with an increased tail on the maturing survival curve.

September 26, 2023 | 12:03 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Candel Therapeutics' initial survival data from its Phase 2 clinical trial of CAN-2409 suggests potential positive impact on the company's stock.
The initial survival data from Candel Therapeutics' Phase 2 clinical trial of CAN-2409 in non-small cell lung cancer is promising. This could potentially lead to increased investor confidence in the company, thereby positively impacting the company's stock price in the short term.
CONFIDENCE 85
IMPORTANCE 80
RELEVANCE 100